Healthcare · Biotechnology
Price
$0.76
Market Cap
$4.2M
Employees
2
Beta
1.71
Avg Volume
156,334
CEO
Jerome D. Jabbour
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Runs with full report
Price Overview
Last updated: Jul 11, 2026 4:39pm (just now)
Current data · timestamped when a report runs
$0.76
Change · Jul 11
+0.13 (+20.46%)
Day Range
$0.62 – $0.91
52-Week Range
$0.48 – $3.09
50-Day MA
$0.68
200-Day MA
$0.85
Volume
1,642,003.00
Share Structure
Outstanding
5,553,651.00
Float
4,381,462.00
Free Float
78.9%
Normal free float
— 78.9% of shares trade freely, ~21.1% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (4.4M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.38
Stock Price: $0.76
EPS (Diluted): -2.00
EPS (Diluted): -2.00
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.66
Stock Price: $0.76
Total Equity: $4.83M
Shares: 5,474,129
Total Equity: $4.83M
Shares: 5,474,129
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.30
Market Cap: $4.19M
Total Debt: $696,000
Cash: $4.00M
EBITDA: -$9.89M
Total Debt: $696,000
Cash: $4.00M
EBITDA: -$9.89M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$562,840
Market Cap: $4.19M
Total Debt: $696,000
Cash: $4.00M
Total Debt: $696,000
Cash: $4.00M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $0.76
Revenue: $0.00
Shares: 5,474,129
Revenue: $0.00
Shares: 5,474,129
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$456,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$6.96M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$10.35M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-204.3%
Net Income: -$10.35M
Total Equity: $4.83M
Total Equity: $4.83M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-155.6%
Operating Income: -$6.96M
Tax Rate: 0.0%
Equity: $4.83M
Total Debt: $696,000
Cash: $4.00M
Tax Rate: 0.0%
Equity: $4.83M
Total Debt: $696,000
Cash: $4.00M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.79
Current Assets: $4.08M
Current Liabilities: $1.46M
Current Liabilities: $1.46M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.14
Short-Term Debt: $696,000
Long-Term Debt: $0.00
Total Debt: $696,000
Total Equity: $4.83M
Long-Term Debt: $0.00
Total Debt: $696,000
Total Equity: $4.83M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 5,474,129
Shares: 5,474,129
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.88
Total Equity: $4.83M
Shares: 5,474,129
Shares: 5,474,129
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.28
Operating CF: -$7.01M
CapEx: $0.00
Shares: 5,474,129
CapEx: $0.00
Shares: 5,474,129
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.76
Stock Price: $0.76
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$10.35M
Net Income: -$10.35M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares MTNB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 11, 2026 2:02pm (2h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $33,000 | $3.2M | $1.1M | $0 | $0 |
| Cost of Revenue | $14.6M | $16.7M | $941,000 | $972,000 | $456,000 |
| Gross Profit | -$14.6M | -$13.5M | $155,000 | $-972,000 | $-456,000 |
| Operating Expenses | $10.2M | $11.1M | $23.9M | $19.2M | $6.5M |
| Operating Income | -$24.7M | -$24.6M | -$23.8M | -$20.2M | -$7.0M |
| Net Income | -$23.3M | -$21.0M | -$22.9M | -$24.3M | -$10.3M |
| EBITDA | -$23.0M | -$20.6M | -$22.0M | -$19.2M | -$9.9M |
| EPS | $-5.04 | $-3.00 | $-5.28 | $-4.98 | $-2.00 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 11, 2026 2:02pm (2h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $21.0M | $6.9M | $4.8M | $7.3M | $4.0M |
| Total Current Assets | $51.0M | $34.5M | $15.5M | $8.0M | $4.1M |
| Total Assets | $61.3M | $78.9M | $25.1M | $12.6M | $7.2M |
| Current Liabilities | $4.3M | $4.3M | $2.6M | $2.7M | $1.5M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $8.8M | $42.2M | $5.9M | $5.1M | $2.4M |
| Total Equity | $52.5M | $36.6M | $19.2M | $7.6M | $4.8M |
| Retained Earnings | -$131.6M | -$152.6M | -$175.6M | -$199.8M | -$210.8M |
Cash Flow (Annual)
Last updated: Jul 11, 2026 2:02pm (2h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.2M | -$19.2M | -$15.3M | -$15.9M | -$7.0M |
| Capital Expenditure | $-260,000 | $-892,000 | $-218,000 | $0 | $0 |
| Free Cash Flow | -$15.5M | -$20.0M | -$15.5M | -$15.9M | -$7.0M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $8.5M | -$14.2M | -$2.0M | $2.5M | -$3.3M |
Analyst Estimates (Annual)
Last updated: Jul 11, 2026 2:02pm (2h ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$63.9M $63.9M – $63.9M
|
$93.3M $93.3M – $93.3M
|
$45.2M $45.2M – $45.2M
|
$120.1M $120.1M – $120.1M
|
| EBITDA |
-$12.8M -$12.8M – -$12.8M
|
-$18.7M -$18.7M – -$18.7M
|
-$9.0M -$9.0M – -$9.0M
|
-$24.0M -$24.0M – -$24.0M
|
| Net Income |
-$8.2M -$8.2M – -$8.2M
|
-$27.4M -$27.4M – -$27.4M
|
-$13.7M -$13.7M – -$13.7M
|
$60.2M $60.2M – $60.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 11, 2026 2:02pm (2h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +9,560.6% | -65.6% | -100.0% | — |
| Gross Profit Growth | +7.3% | +101.1% | -727.1% | +53.1% |
| Operating Income Growth | +0.6% | +3.4% | +15.2% | +65.5% |
| Net Income Growth | +9.8% | -9.3% | -5.7% | +57.3% |
| EBITDA Growth | +10.3% | -6.6% | +12.8% | +48.5% |
Insider Trading (Recent)
Last updated: Jul 11, 2026 2:02pm (2h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-04-30 | NEUGEBOREN EDWARD | A-Award | 11,600.00 | $0.59 | $6,844 |
| 2025-04-30 | Smith Robin L | A-Award | 11,600.00 | $0.59 | $6,844 |
| 2025-04-30 | D An Evelyn | A-Award | 11,600.00 | $0.59 | $6,844 |
| 2025-04-30 | Jabbour Jerome D | A-Award | 70,100.00 | $0.59 | $41,359 |
| 2025-04-30 | Murphy Keith | A-Award | 11,600.00 | $0.59 | $6,844 |
| 2025-02-13 | STERN ADAM K | 0.00 | $0.00 | $0 | |
| 2025-02-13 | STERN ADAM K | 2,399,318.00 | $0.00 | $0 | |
| 2025-02-13 | STERN ADAM K | 4,798,636.00 | $0.00 | $0 | |
| 2025-04-08 | Sanitam Partners LLC | P-Purchase | 2,399,318.00 | $0.64 | $1.5M |
| 2025-04-08 | Sanitam Partners LLC | P-Purchase | 703.00 | $0.59 | $412 |
| 2025-04-08 | EIDE ROBERT J | P-Purchase | 1,679,182.00 | $0.64 | $1.1M |
| 2025-04-08 | EIDE ROBERT J | P-Purchase | 492.00 | $0.59 | $288 |
| 2025-04-08 | Pembroke & Partners LLC | P-Purchase | 1,679,182.00 | $0.64 | $1.1M |
| 2025-04-08 | Pembroke & Partners LLC | P-Purchase | 492.00 | $0.59 | $288 |
| 2025-03-11 | Murphy Keith | 0.00 | $0.00 | $0 | |
| 2025-03-11 | NEUGEBOREN EDWARD | 0.00 | $0.00 | $0 | |
| 2025-02-13 | EIDE ROBERT J | 0.00 | $0.00 | $0 | |
| 2025-02-13 | EIDE ROBERT J | 1,679,182.00 | $0.00 | $0 | |
| 2025-02-13 | EIDE ROBERT J | 839,591.00 | $0.00 | $0 | |
| 2025-02-13 | Sanitam Partners LLC | 1,199,659.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for MTNB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for MTNB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.406 · 9aebe10a · 2026-07-11 16:07:30